Many early cell therapies failed due to the impractical cost and complexity of individual manufacturing for each patient. Companies now succeeding are developing "off-the-shelf" treatments that don't require patient matching or immune suppression, creating a more scalable and commercially viable model similar to traditional drugs.
A common pitfall for science-led companies is getting lost in the pursuit of academic perfection while forgetting the ultimate goal: developing a marketable product. Success requires shifting focus from perfect science to creating a product that is "good enough" to help patients, a mindset crucial for navigating the complexities of drug development.
An experienced biotech CEO reveals a cynical but practical truth: the baseline for a good board is one that simply isn't destructive and doesn't make the CEO's job harder. New leaders should prioritize building a board with supportive, independent members who offer more than just investment capital, as investor-heavy boards can lack a company-first perspective.
While a board is crucial, it also determines a CEO's employment, creating a barrier to complete transparency about personal shortcomings or critical challenges. An external mentor provides a safe, confidential space for a CEO to be vulnerable, bounce ideas, and get candid advice on sensitive issues like team problems or hiring mistakes without fear of reprisal.